A Phase 1 Study of MORAb-004 in Patients With Solid Tumor
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tolerability and Safety
Tolerability and the safety profile of multiple intravenous (IV) infusions of MORAb-004 in Japanese participants with solid tumors.
Up to 30 months
Eisai Co., Ltd.
Japan: Ministry of Health, Labor and Welfare